先进磁共振成像对常规形态学分析鉴别良性及恶性非脂肪性软组织肿瘤的附加价值
前瞻性纳入2009年11月至2017年8月288例非脂肪性软组织肿瘤患者,评估DWI、质子MR波谱和动态对比增强灌注相对于常规MRI的附加价值。常规MRI后判定为不确定的非黏液性肿瘤中,优先使用先进MRI技术可使不确定肿瘤数量减少约30%,DWI单独敏感度最高(91.8%),联合技术特异度可达100%。
要点
- 常规MRI形态学可判定良恶性时诊断准确率高(R1 87.9%、R2 83.7%),无需先进影像技术
- 常规MRI后不确定的非黏液性肿瘤,优先使用先进MRI可使不确定数量减少约30%
- DWI是先进技术的基石,敏感度最高(91.8%);联合技术可获得最佳特异度(100%)
核心结论
- 优先使用先进MRI技术可使常规MRI分析后判定为不确定的非黏液性非脂肪性软组织肿瘤数量减少约30%。
- 常规MRI形态学可判定良恶性时诊断性能高,无需先进影像技术。
- DWI是先进影像技术的基石,敏感度最高(91.8%);联合先进技术可获得最佳特异度(100%)。
- 提出了一套基于证据的先进MRI评估算法,可对28.1%至30.1%的不确定非黏液性肿瘤进行定性。
研究设计与样本
- 前瞻性研究,纳入2009年11月至2017年8月288例接受常规及先进MRI的非脂肪性软组织肿瘤患者。
- 研究经当地伦理委员会批准,所有患者签署知情同意书。
- 由一名骨肌放射科医生(R1)和一名普通放射科医生(R2)根据形态学MRI特征将肿瘤分类为良性、恶性或不确定。
- 对不确定肿瘤的DWI、质子MR波谱和动态对比增强灌注数据由另外两名放射科医生(R3和R4)分析。
- 以组织学为金标准,评估先进技术单独及联合用于肿瘤良恶性鉴别的价值。
诊断标准与关键数值
- 288例中恶性104例(36.1%)、良性184例(63.9%)。
- 常规MRI分析将99例(R1)和135例(R2)肿瘤分类为良性或恶性,恶性识别准确率分别为R1 87.9%、R2 83.7%。
- R1判定不确定肿瘤189例,对这些肿瘤DWI与质子MR波谱联合的恶性识别准确率最佳(77.4%)。
- DWI单独提供最佳敏感度(91.8%);动态对比增强灌注、DWI和质子MR波谱三者联合提供最佳特异度(100%)。
- 先进影像参数的可重复性为良好至优秀(Kappa和ICC > 0.86)。
临床应用与阅片要点
- 常规MRI形态学可明确良恶性的非脂肪性软组织肿瘤无需追加先进影像技术。
- 常规MRI后仍不确定的非黏液性肿瘤,可优先采用先进MRI技术(以DWI为基石)进一步定性。
- 先进MRI评估算法可对28.1%至30.1%的不确定非黏液性肿瘤实现定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the added value of DWI, qualitative proton MR spectroscopy (H-MRS) and dynamic contrast-enhanced perfusion (DCE-P) to conventional MRI in differentiating benign and malignant non-fatty soft tissue tumors (NFSTT).
METHODS: From November 2009 to August 2017, 288 patients with NFSTT that underwent conventional and advanced MRI were prospectively evaluated. The study was approved by the local ethics committee. All patients signed an informed consent. A musculoskeletal (R1) and a general (R2) radiologist classified all tumors as benign, malignant, or indeterminate according to morphologic MRI features. Then, DWI, H-MRS, and DCE-P data of indeterminate tumors were analyzed by two additional radiologists (R3 and R4). Advanced techniques were considered individually and in combination for tumor benign-malignant differentiation using histology as the gold standard.
RESULTS: There were 104 (36.1%) malignant and 184 (63.9%) benign tumors. Conventional MRI analysis classified 99 tumors for R1 and 135 for R2 as benign or malignant, an accuracy for the identification of malignancy of 87.9% for R1 and 83.7% for R2, respectively. There were 189 indeterminate tumors for R1. For these tumors, the combination of DWI and H-MRS yielded the best accuracy for malignancy identification (77.4%). DWI alone provided the best sensitivity (91.8%) while the combination of DCE-P, DWI, and H-MRS yielded the best specificity (100%). The reproducibility of the advanced imaging parameters was considered good to excellent (Kappa and ICC > 0.86). An advanced MRI evidence-based evaluation algorithm was proposed allowing to characterize 28.1 to 30.1% of indeterminate non-myxoid tumors.
CONCLUSION: The prioritized use of advanced MRI techniques allowed to decrease by about 30% the number of non-myxoid NFSTT deemed indeterminate after conventional MRI analysis alone.
KEY POINTS: • When morphological characterization of non-fatty soft tissue tumors is possible, the diagnostic performance is high and there is no need for advanced imaging techniques. • Following morphologic analysis, advanced MRI techniques reduced by about 30% the number of non-myxoid indeterminate tumors. • DWI is the keystone of advanced imaging techniques yielding the best sensitivity (91.8%). Optimal specificity (> 90%) is obtained by a combination of advanced techniques.
引用
- Dodin G, Salleron J, Jendoubi S, et al. Added-value of advanced magnetic resonance imaging to conventional morphologic analysis for the differentiation between benign and malignant non-fatty soft-tissue tumors. Eur Radiol. 2020. PMID: 32885297. doi:10.1007/s00330-020-07190-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。